Gene signatures in stage II colon cancer: A clinical review

Current Colorectal Cancer Reports

Volumn 8, Issue 3, 2012, Pages 225-231

  Sharif, Saima ^a   O'Connell, Michael J ^b  

^a NSABP Foundation Inc   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant! Online; ColDx; Colon cancer; ColoPrint; Gene signatures; Guanylyl cyclase C; MSI; Numeracy; Oncotype DX RS; Predictive score; Prognostic score; Recurrence score; Stage II

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER STAGING; CLINICAL DECISION MAKING; COLON CANCER; DIAGNOSTIC TEST; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; HUMAN; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84869137663     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-012-0132-7     Document Type: Article

References (54)

1. Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2012. Cancer J Clin. 2012;62:10-29.
2. Edge SE, Byrd DR, Carducci MA. AJCC Cancer Staging Manual 7th ed. 14th ed. New York, NY: Springer; 2010. p. 143-64.
3. Gunderson LL, Jessup JM, Sargent DJ. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28:264-71. This article updates the survival pattern of patients with colon cancer, which is the basis of changes made to the substaging in the AJCC colon cancer staging 7th edition.
4. Green FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlay; 2002 (Chapter 12, pages 113-122).
5. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420.
6. The QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet. 2007;370:2020-9.
7. André T, Boni C, Navarro M. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109.
8. Kuebler JP, Wieand S, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 2007;25(16):2198.
9. Wilkinson NW, Yothers G, Lopa S. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17(4):959-66. This article is a metaanalysis of NSABP C-01 through C-06 showing benefit in outcomes when 5-FU is given in addition to surgery to provide anticipated survival outcome with which to compare modern adjuvant trials.
10. NCCN guidelines Version 3.2012. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp
11. O'Conner ES, Greenblatt DY, LoConte NK. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381-8. This article provides information that older patients with stage II colon cancer and at least one clinicopathologic risk factor do not benefit from adjuvant chemotherapy.
12. Benson AB, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-19.
13. Adjuvant! Online: www.adjuvantonline.com
14. Numeracy: www.mayoclinic.com/calcs
15. Sargent DJ, Marsoni S, Monges G. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28 (30):3216-26. This article shows that stage II colon cancer patients do not benefit from adjuvant 5-FU-based therapy.
16. Waldman SA, Hyslop T, Schulz S, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009;301(7):745-52.
17. Sargent DJ, Resnick MB, Meyers MO. Evaluation of Guanylyl Cyclase C lymph node status for colon cancer staging and prognosis. Ann Surg Oncol. 2011;18(12):3261-70. This article shows the importance of detecting guanylyl cyclase C as a marker for metastatic disease in the lymph nodes in stage II patients without histologic evidence of positive nodes.
18. Gal R, Sadikov E, Sulkes J, et al. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum. 2004;47(7):1216.
19. Sargent DJ, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872-7.
20. Dotor E, Cuatrecases M, Martínez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol. 2006;24(10):1603-11.
21. Ahnen DJ, Feigl P, Quan G. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res. 1998;58:1149-58.
22. Elsaleh H, Powell B, Soontrapornchai P. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology. 2000;58:52-9.
23. Westra JL, Schaapveld M, Hollema H. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635-43.
24. Roth AD, Tejpar S, Yan P. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol. 2009;27(4002):169s. This abstract provides information that molecular markers in stage II and III colon cancer have stage-specific prognostic information and may represent different diseases rather than sequential steps in the evolution of colon cancer.
25. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57.
26. Storojeva I, Boulay JL, Heinimann K. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep. 2005;14:241-9.
27. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126:394-401.
28. González-García I, Moreno V, Navarro M. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst. 2000;92:544-9.
29. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene. 2004;23:1377-91.
30. Wang Y, Jatkoe T, Zhang Y. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564-71.
31. Barrier A, Boelle PY, Roser F. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol. 2006;24:4685-91.
32. Eschrich S, Yang I, Bloom G. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526-35.
33. O'Connell MJ, Lavery I, Yothers G. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937-44. This article details the process of gene selection and validation to develop the 12-gene OncotypeDX Recurrence Score from formalin-fixed paraffin embedded tissue.
34. Dukes CE. The classification of cancer of the rectum. J Pathol Bact. 1932;35:323-32.
35. Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958;12:309-20.
36. Gray RG, Quirke P, Handley K. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611-9. This article describes the external validation of the 12-gene OncotypeDX Recurrence Score in the QUASAR and CALGB 9581 trials.
37. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet. 2002;360:1381-91.
38. de Bruin M, van Capel T, Van der Born K, et al. Role of plateletderived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer. 2003;88:957-64.
39. van Triest B, Pinedo HM, Blaauwgeers JL, et al. Prognostic role of thymidine synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor and proliferation markers in colorectal cancer. Clin Cancer Res. 2000;6:1063-72.
40. van Kuilenburg AB. Screening for dihyrodropyrimidine dehydrogenase deficiency: To do or not to do, that's the question. Cancer Invest. 2006;24:215-7.
41. Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother. 2004;16(4):25-30.
42. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322-7.
43. Ichikawa W, Uetake H, Shirota Y, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expression in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res. 2003;9:786-91.
44. O'Connell MJ, Lee M, Lopatin M, et al.: Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5-FU/LV (FU) and 5-FU/LV+oxaliplatin (FU+Ox). Being presented at American Society of Clinical Oncology June 1-5th 2012. Poster Discussion Session. Abstract #3512. This abstract provides results of validation study of OncotypeDX Recurrence Score (RS) on NSABP C-07 patients showing that the RS is prognostic of outcomes in patients treated with 5-FU and degree of benefit from oxaliplatin is a function of risk.
45. Salazar R, Roepman P, Capella G. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17-24. This article describes the process of development of the 18-gene ColoPrint assay using Agilent 44K oligonucleotide assay from fresh frozen tissue.
46. Tabernero J, Moreno V, Rosenberg R. Clinical and technical validation of genomic classifier (ColoPrint) for predicting outcomes in stage II colon cancer. J Clin Oncol. 2012;30(4):abstr 384. This abstract provides the validation study for the 18-gene ColoPrint.
47. Kennedy RD, Bylesjo M, Kerr P. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29 (35):4620-8. This article provides the development and validation of the ColDx which is a 634-gene microarray analysis of formalin fixed paraffin embedded tissue.
48. Nosho K, Yamamoto H, Taniguchi H, et al. Interplay of insulinlike growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res. 2004;10:7950-7.
49. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression. Gastroenterology. 1996;110:375-82.
50. Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55:234-42.
51. Giacomini CP, Leung SY, Chen X, et al. A gene expression signature of genetic instability in colon cancer. Cancer Res. 2005;65:9200-5.
52. de Gramont A, Hubbard J, Shi Q, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2012;28(3):460-5.
53. van't Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
54. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7:278.